Loading clinical trials...
Loading clinical trials...
A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis
Conditions
Interventions
Bimekizumab
Certolizumab pegol
+1 more
Locations
34
United States
As0013 908
Ormond Beach, Florida, United States
As0013 903
Lincoln, Nebraska, United States
As0013 902
Oklahoma City, Oklahoma, United States
As0013 906
Memphis, Tennessee, United States
As0013 202
Kladno, Czechia
As0013 205
Ostrava, Czechia
Start Date
October 4, 2017
Primary Completion Date
May 25, 2020
Completion Date
May 25, 2020
Last Updated
July 27, 2023
NCT04402086
NCT07261644
NCT04751396
NCT06707194
NCT06988813
NCT05866614
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions